Driving the industry pipeline of next generation immune checkpoint modulators
Returning for the third year, ICI Boston 2017 focuses exclusively on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations, from pathway validation to clinical success.
Gain in-depth insights from Merck, BMS, Genentech, MedImmune, Novartis, EMD Serono and transform the success of your immuno-oncology approach.
Combining data driven case studies with interactive experience sharing sessions, this year’s program will provide cutting edge insights into rational combination strategies, patient stratification biomarkers, novel checkpoint pathways, and emerging clinical trial data.
‘Great Meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy.’ Genentech
‘I took away a lot of information and really enjoyed the conference…..I learned a lot and enjoyed it.’ Merck
‘Great meeting for an over-view on the iONC landscape. I enjoyed the versatility of the talks and the opportunity to network with peers.’ EMD Serono